Oral Solid Dose Manufacturing for Mid-Sized Pharma: Scalable Partnership from Development to Commercial Production

Mid-sized pharmaceutical companies face a strategic tension that defines their manufacturing decisions: how to move products from development to commercial scale with speed, quality and supply chain reliability—without the capital burden of building and maintaining internal manufacturing infrastructure.

The answer increasingly lies in selecting the right contract manufacturing partner. But not all CMOs are built the same. For mid-sized pharma companies, the difference between a capacity-filling vendor and a true drug production partner can determine whether a product reaches patients on time—or stalls in the pharma supply chain.

The Mid-Sized Pharma Manufacturing Challenge

Mid-sized pharma companies often operate in a difficult middle ground. They lack the internal manufacturing scale of large pharmaceutical organizations, yet they face the same regulatory expectations, quality requirements and market pressures. Building dedicated oral solid dose capacity requires significant capital investment, specialized expertise and ongoing maintenance—resources that may be better allocated to R&D and commercialization.

At the same time, mid-sized companies cannot afford the risks that come with unreliable contract manufacturing: missed timelines, quality deviations, supply interruptions or partners who deprioritize their projects when larger clients demand attention.

The result is a clear set of requirements for any contract manufacturing relationship:

• Scalable capacity that can grow with product demand
• Integrated quality systems that meet global regulatory standards
• Technical expertise to solve formulation and process challenges
• Reliable supply chain performance and on-time delivery
• A partner who treats every product as if it were their own

Why an Embedded CMO Model Works for Mid-Sized Pharma

AbbVie Contract Manufacturing operates as an embedded CMO—a self-contained business unit within AbbVie Inc. that leverages the parent company's infrastructure, expertise and quality systems. This model offers mid-sized pharma companies distinct advantages over stand-alone CMOs.

Unlike stand-alone CMOs that must fill capacity to remain financially viable, an embedded CMO shares in the success of its parent organization. This means AbbVie CMO can select partners that best fit its technologies and expertise, rather than overcommitting to fill capacity. The result: every project receives the attention and resources it needs, regardless of company size.

For mid-sized pharma companies, this translates to access to big-pharma infrastructure—validated processes, global regulatory expertise, established quality systems—without the typical CMO risk of being deprioritized when larger clients demand attention.

Oral Solid Dose Capabilities Built for Flexibility & Scale

AbbVie Contract Manufacturing operates oral solid dose manufacturing across six facilities in the United States and Europe, providing one of the most effective global networks for mid-sized pharma companies seeking both flexibility and redundancy.

Core oral solid dose manufacturing capabilities include:

• Blending: V-blenders (2 ft³ to 150 ft³ scale) and bin blenders
• Granulation & drying: Roller compaction, high shear granulation (75L, 300L and 1,200L), spray granulation (400L to 1,100L), melt granulation (18mm to 70mm screw size), fluid bed drying and tray drying
• Milling: Impact milling and screen milling
• Compression: Single layer, multi-layer and mini tab
• Coating: Tablet coating, particle coating and active coating
• Encapsulation: Granule filled, liquid filled (hard gelatin), mini tab filled and over encapsulation

This range of capabilities allows AbbVie CMO to support flexible scales—from boutique clinical batches to large-scale commercial production—within a single integrated network.

Integrated Support from Development Through Commercial Production

One of the most significant risks in the pharma supply chain is the handoff between development and commercial manufacturing. When these functions are siloed—or handled by different partners—technology transfer delays, process deviations and quality issues become more likely.

AbbVie Contract Manufacturing offers integrated support across the full product lifecycle. Development and commercial manufacturing teams work within the same quality systems, using the same validated processes and equipment platforms. This continuity reduces tech transfer risk and accelerates the path from clinical supply to commercial launch.

For difficult-to-formulate compounds, AbbVie CMO offers hot melt extrusion (HME) capabilities backed by over 30 years of experience and more than 100 HME development programs. HME can improve bioavailability for poorly soluble APIs—a common challenge for mid-sized pharma companies working with complex molecules.

Quality Systems That Meet Global Regulatory Expectations

For mid-sized pharma companies, regulatory compliance is non-negotiable. AbbVie Contract Manufacturing operates under the same world-class quality systems used for AbbVie's own products—systems that have supported global regulatory approvals across multiple markets.

Key quality and regulatory advantages include:

• cGMP-compliant manufacturing across all facilities
• Established relationships with FDA, EMA and other global regulatory agencies
• Integrated quality agreements with careful data handling and IP protection
• Potent compound handling capabilities (<1μg/m³) for HPAPI products
• Extensive controlled temperature warehousing (2°C to 8°C) for API and drug product

Because AbbVie CMO operates within a company that markets its own products globally, it maintains up-to-date working knowledge of evolving regulatory requirements—an advantage that translates to fewer surprises at submission and inspection.

Packaging Capabilities to Complete the Supply Chain

Oral solid dose manufacturing does not end at compression or encapsulation. AbbVie Contract Manufacturing offers comprehensive packaging capabilities to complete the supply chain:

• Blisters
• Bottles
• Sachets and sticks
• Wallets

All packaging operations are compliant with serialization and aggregation requirements, ensuring traceability and regulatory compliance across global markets.

40+ Years as a Trusted Drug Production Partner

AbbVie Contract Manufacturing has been carefully safeguarding client IP and patient supply for over 40 years as a committed third-party manufacturing partner. This track record spans thousands of satisfied partners—from virtual biotech companies to large pharmaceutical organizations.

The embedded CMO model means AbbVie CMO is motivated to build long-term relationships that support the future growth of both parties. Every drug product is treated as if it were AbbVie's own, with the same rigor, attention and accountability.

Start a Conversation

AbbVie Contract Manufacturing is a seasoned partner for mid-sized pharma companies seeking reliable oral solid dose manufacturing. To discuss how AbbVie CMO can support your development and commercialization goals, contact us